Wells Fargo
ESLA icon

Wells Fargo’s Estrella Immunopharma ESLA Stock Holding History

Wells Fargo’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-264,388
Closed -$280K – 7383
2026
Q1 		$280K Buy
+264,388
New +$304K ﹤0.01% 4488
2024
Q2 		– Sell
-74
Closed -$92 – 7060
2024
Q1 		$92 Buy
74
+1
+1% +$1 ﹤0.01% 6682
2023
Q4 		$81 Buy
+73
New +$110 ﹤0.01% 6819

Other funds holding ESLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo's ESLA Position: Q2 2026 in Review

Wells Fargo sold out of Estrella Immunopharma (ESLA) in Q2 2026, closing a stake of 264,388 shares — an estimated $280K sold.

Wells Fargo first reported a position in ESLA in Q4 2023 and held it in 3 quarters. The position peaked at $280K in Q1 2026. 15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

  • Wells Fargo reported no remaining Estrella Immunopharma position as of Q2 2026 after selling out during the quarter.
  • Wells Fargo sold 264,388 Estrella Immunopharma shares in Q2 2026, an estimated $280K.
  • Wells Fargo first reported a position in Estrella Immunopharma in Q4 2023 and held it in 3 quarters.
  • Wells Fargo's Estrella Immunopharma position peaked at $280K in Q1 2026.
  • 15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.